Merck's $9.5bn Cubist buy overshadowed by court decision
This article was originally published in Scrip
Merck & Co has agreed to acquire antibiotics specialist Cubist Pharmaceuticals in a cash deal worth about $9.5bn. Merck will pay $8.4bn in cash for Cubist's stock at $102 per share (a 35% premium to the company's average stock price over the previous five days), and the deal includes $1.1bn in net debt.
You may also be interested in...
Antibacterials have been part of Merck's mission for decades, despite the market challenges, and it's expecting two new approvals this year. Infectious disease VP Joan Butterton talks about tackling those challenges and incentives that may help the industry address antimicrobial resistance.
Medicxi's new $300m venture fund will benefit from the expertise of former GSK R&D leader Moncef Slaoui, while ex-CEO Witty will inform portfolio strategy at Hatteras. Also, Kaleido hires past Cubist CEO and brings VC funding to $65m, while Gilead sells $3bn in debt to fund Kite deal.
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.